X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3591) 3591
Book Review (681) 681
Newspaper Article (285) 285
Publication (199) 199
Newsletter (72) 72
Magazine Article (42) 42
Book Chapter (26) 26
Trade Publication Article (16) 16
Conference Proceeding (12) 12
Dissertation (3) 3
Book / eBook (2) 2
Web Resource (2) 2
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hyperglycemia (3018) 3018
index medicus (2584) 2584
humans (2164) 2164
diabetes (2132) 2132
female (1352) 1352
male (1323) 1323
glucose (1075) 1075
risk factors (885) 885
endocrinology & metabolism (878) 878
insulin (877) 877
middle aged (875) 875
diabetes mellitus (805) 805
adult (802) 802
type 2 diabetes (796) 796
aged (643) 643
animals (539) 539
research (533) 533
prevalence (524) 524
obesity (516) 516
health aspects (503) 503
mortality (502) 502
analysis (492) 492
mellitus (492) 492
blood glucose - metabolism (451) 451
care and treatment (447) 447
insulin resistance (439) 439
hypoglycemic agents - therapeutic use (437) 437
studies (407) 407
risk (375) 375
diabetes mellitus, type 2 - drug therapy (367) 367
oxidative stress (363) 363
blood sugar (357) 357
food science & technology (354) 354
glycemic control (346) 346
hypoglycemia (343) 343
dextrose (335) 335
pregnancy (334) 334
hyperglycemia - prevention & control (322) 322
hypertension (316) 316
medicine (309) 309
patients (307) 307
diabetes therapy (305) 305
metabolism (303) 303
rats (301) 301
diabetes mellitus, type 2 - blood (298) 298
body mass index (295) 295
management (295) 295
complications (293) 293
blood glucose - analysis (292) 292
research article (284) 284
population (273) 273
metabolic syndrome (265) 265
nutrition & dietetics (262) 262
medicine, general & internal (259) 259
hyperglycemia - epidemiology (258) 258
insulin-resistance (254) 254
diagnosis (252) 252
hyperglycemia - drug therapy (248) 248
cross-sectional studies (246) 246
cardiovascular disease (242) 242
diabetics (241) 241
medical research (238) 238
adolescent (237) 237
epidemiology (236) 236
association (229) 229
diet (225) 225
internal medicine (225) 225
prevention (224) 224
glycated hemoglobin a - analysis (220) 220
young adult (218) 218
rodents (217) 217
glucose metabolism (216) 216
hypoglycemic agents - administration & dosage (211) 211
medicine & public health (209) 209
hyperglycemia - blood (208) 208
adults (207) 207
antioxidants (206) 206
disease (206) 206
insulin - therapeutic use (206) 206
cholesterol (202) 202
complications and side effects (201) 201
abridged index medicus (200) 200
hospitals (199) 199
diabetes mellitus, type 2 - complications (198) 198
retrospective studies (197) 197
metabolic disorders (196) 196
physiological aspects (194) 194
mice (192) 192
blood pressure (187) 187
cohort studies (183) 183
treatment outcome (183) 183
public health (181) 181
diabetes mellitus, type 2 - epidemiology (180) 180
socioeconomic factors (179) 179
risk-factors (177) 177
aged, 80 and over (176) 176
cardiovascular-disease (176) 176
pharmacology & pharmacy (175) 175
hyperglycemia - complications (174) 174
glycated hemoglobin a - metabolism (173) 173
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3985) 3985
Spanish (11) 11
Portuguese (10) 10
German (4) 4
Russian (3) 3
French (2) 2
Korean (2) 2
Polish (2) 2
Bosnian (1) 1
Bulgarian (1) 1
Chinese (1) 1
Croatian (1) 1
Hungarian (1) 1
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2017, Volume 19, Issue 12, pp. 1688 - 1697
Aims: To estimate the long-term cost-effectiveness of exenatide twice daily vs insulin glargine once daily as add-on therapy to oral antidiabetic agents (OADs)... 
pharmaco‐economics | antidiabetic drug | cost‐effectiveness | type 2 diabetes | insulin therapy | exenatide | cost-effectiveness | pharmaco-economics | METFORMIN | RISK-FACTORS | CARDIOVASCULAR OUTCOMES | RETROSPECTIVE COHORT | MELLITUS | MODEL | ADHERENCE | ENDOCRINOLOGY & METABOLISM | LIFETIME HEALTH OUTCOMES | WEIGHT-GAIN | UTILITY | Hypoglycemia - epidemiology | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diabetic Cardiomyopathies - economics | Models, Economic | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Diabetic Angiopathies - prevention & control | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Diabetic Angiopathies - economics | Direct Service Costs | Administration, Oral | Venoms - adverse effects | Hyperglycemia - economics | Drug Therapy, Combination - economics | Diabetic Angiopathies - therapy | Diabetic Cardiomyopathies - epidemiology | Venoms - therapeutic use | Quality of Life | Hyperglycemia - epidemiology | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Cardiovascular Diseases - therapy | Diabetes Mellitus, Type 2 - economics | Hypoglycemia - prevention & control | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Peptides - economics | Venoms - administration & dosage | Diabetic Cardiomyopathies - prevention & control | Diabetic Cardiomyopathies - therapy | Hypoglycemia - economics | Diabetes Mellitus, Type 2 - complications | Cardiovascular Diseases - economics | Insulin Glargine - adverse effects | Drug Administration Schedule | Venoms - economics | Insulin Glargine - economics | Insulin Glargine - therapeutic use | China - epidemiology | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Cost-Benefit Analysis | Incretins - adverse effects | Diabetic Angiopathies - epidemiology | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hyperglycemia - therapy | Peptides - adverse effects | Peptides - therapeutic use | Incretins - economics | Type 2 diabetes | Insulin | Analysis | Diabetes therapy | Literature reviews | Databases | Diabetes mellitus | Clinical trials | Diabetes | Cost analysis | Hypoglycemia | Patients | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1921 - 1927
Aims The recent LIRA-SWITCH trial showed that switching from sitagliptin 100 mg to liraglutide 1.8 mg led to statistically significant and clinically relevant... 
cost‐effectiveness | GLP‐1 analogue | type 2 diabetes | incretin therapy | liraglutide, sitagliptin | cost-effectiveness | GLP-1 analogue | liraglutide | VALIDATION | UTILITY VALUES | MELLITUS | MODEL | sitagliptin | DISEASE | ENDOCRINOLOGY & METABOLISM | MULTIFACTORIAL INTERVENTION | COMPLICATIONS | OUTCOMES | Anti-Obesity Agents - economics | Hypoglycemia - therapy | Overweight - complications | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Overweight - drug therapy | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Anti-Obesity Agents - adverse effects | Diabetes Mellitus, Type 2 - economics | Diabetes Complications - therapy | Diabetes Mellitus, Type 2 - metabolism | Models, Economic | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Liraglutide - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Hypoglycemia - prevention & control | Overweight - metabolism | Glucagon-Like Peptide-1 Receptor - metabolism | Diabetes Complications - epidemiology | Hypoglycemia - economics | Hypoglycemia - chemically induced | Overweight - economics | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Diabetes Complications - prevention & control | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hyperglycemia - economics | Risk Factors | Sitagliptin Phosphate - economics | Diabetes Complications - economics | Health Care Costs | Liraglutide - adverse effects | Cost-Benefit Analysis | Liraglutide - therapeutic use | Quality of Life | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Hyperglycemia - therapy | Hypoglycemic Agents - adverse effects | United Kingdom - epidemiology | Glucagon-Like Peptide-1 Receptor - agonists | Cohort Studies | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Hypoglycemic agents | Cost benefit analysis | Health aspects | Analysis | Body mass index | Costs | Statistical analysis | Life span | Diabetes mellitus | Hemoglobin | Diabetes | Diabetes mellitus (non-insulin dependent) | Patients | Clinical outcomes | Index Medicus
Journal Article
Diabetic Medicine, ISSN 0742-3071, 07/2015, Volume 32, Issue 7, pp. 890 - 898
Dapagliflozin is a selective sodium–glucose co–transporter–2 (SGLT‐2) inhibitor licensed in the European Union (EU) for use in people with Type 2 diabetes... 
HEALTH-RELATED UTILITY | INSULIN | THERAPY | MODELS | SAXAGLIPTIN | ENDOCRINOLOGY & METABOLISM | HYPOGLYCEMIA | WEIGHT-GAIN | COMPLICATIONS | INADEQUATE GLYCEMIC CONTROL | STRATEGIES | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Humans | Middle Aged | Male | Diabetes Complications - therapy | Weight Loss - drug effects | Metformin - adverse effects | Metformin - economics | Sodium-Glucose Transport Proteins - metabolism | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Quality-Adjusted Life Years | Hyperglycemia - prevention & control | Hyperglycemia - economics | Diabetes Complications - economics | Drug Therapy, Combination - economics | Overweight - prevention & control | Overweight - therapy | Glucosides - economics | Hypoglycemic Agents - adverse effects | Cohort Studies | Metformin - therapeutic use | Diabetes Mellitus, Type 2 - economics | Risk | Diabetes Mellitus, Type 2 - metabolism | Sulfonylurea Compounds - economics | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Benzhydryl Compounds - adverse effects | Overweight - epidemiology | Diabetes Complications - epidemiology | Female | Glucosides - therapeutic use | Hypoglycemia - economics | Hypoglycemia - chemically induced | Overweight - economics | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Diabetes Complications - prevention & control | Sulfonylurea Compounds - therapeutic use | Benzhydryl Compounds - economics | Sulfonylurea Compounds - adverse effects | Health Care Costs | Cost-Benefit Analysis | Sodium-Glucose Transport Proteins - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Hyperglycemia - therapy | United Kingdom - epidemiology | Type 2 diabetes | Analysis | Development and progression | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Index Medicus
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 10/2016, Volume 116, Issue 8, pp. 1336 - 1345
The world's fisheries and aquaculture industries produce vast amounts of protein-containing by-products that can be enzymatically hydrolysed to smaller... 
Obesity | Herring | Salmon | Cholesterol | Bioactive motifs | IMPROVES INSULIN SENSITIVITY | METABOLIC SYNDROME | COD PROTEIN | OMEGA-3-FATTY-ACIDS | RANDOMIZED-TRIAL | RISK | DIABETES-MELLITUS | NUTRITION & DIETETICS | PEPTIDES | HDL-CHOLESTEROL | CORONARY-HEART-DISEASE | Anti-Obesity Agents - economics | Obesity - diet therapy | Hypoglycemic Agents - economics | Fisheries - economics | Fish Proteins - adverse effects | Male | Anti-Obesity Agents - therapeutic use | Fish Proteins - economics | Weight Gain | Biomarkers - metabolism | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Protein Hydrolysates - chemistry | Fish Proteins - chemistry | Obesity - complications | Obesity - physiopathology | Fish Products - adverse effects | Biomarkers - blood | Hyperlipidemias - prevention & control | Rats, Zucker | Protein Hydrolysates - economics | Anti-Obesity Agents - chemistry | Hypoglycemic Agents - adverse effects | Adipose Tissue, White - metabolism | Anti-Obesity Agents - adverse effects | Diabetes Mellitus, Type 2 - diet therapy | Diabetes Mellitus, Type 2 - metabolism | Adiposity | Fish Proteins - therapeutic use | Dietary Supplements - adverse effects | Diabetes Mellitus, Type 2 - complications | Hyperlipidemias - complications | Fatty Acids, Omega-3 - metabolism | Protein Hydrolysates - therapeutic use | Hypoglycemic Agents - chemistry | Protein Hydrolysates - adverse effects | Industrial Waste - analysis | Amino Acid Motifs | Industrial Waste - economics | Obesity - metabolism | Dietary Supplements - economics | Diabetes Mellitus, Type 2 - blood | Animals | Fish Products - economics | Aquaculture - economics | Hyperlipidemias - etiology | Fatty Acids, Omega-3 - blood | Food-Processing Industry - economics | Proteins | Nutrition research | Diet | Rodents | Fish | Fatty acids | Index Medicus
Journal Article
Journal Article
Journal of Diabetes and Its Complications, ISSN 1056-8727, 2017, Volume 31, Issue 4, pp. 742 - 747
Abstract Background The financial impact of intensive (blood glucose [BG] 100–140 mg/dl [5.5–7.8 mM] vs. conservative (141–180 mg/dl (7.9–10.0 mM) glucose... 
Endocrinology & Metabolism | Hyperglycemia | Health economics | Surgery complications | CABG | Algorithm | Diabetes mellitus | MORTALITY | GLYCEMIC CONTROL | CORONARY | DIABETES-MELLITUS | CARDIAC-SURGERY | GLUCOSE MANAGEMENT | ENDOCRINOLOGY & METABOLISM | ECONOMIC OUTCOMES | COMPLICATIONS | CRITICALLY-ILL PATIENTS | BYPASS GRAFT PATIENTS | Diabetes Mellitus - blood | Hospital Costs | Insulin - economics | Postoperative Complications - economics | Diabetic Angiopathies - surgery | Coronary Artery Disease - surgery | Hypoglycemic Agents - economics | Humans | Middle Aged | Postoperative Complications - prevention & control | Diabetic Cardiomyopathies - surgery | Male | Diabetic Cardiomyopathies - economics | Cost Savings | Diabetes Mellitus - economics | Hypoglycemic Agents - administration & dosage | Diabetic Angiopathies - complications | Female | Insulin Infusion Systems - economics | Hypoglycemic Agents - therapeutic use | Length of Stay | Diabetic Angiopathies - economics | Costs and Cost Analysis | Blood Glucose - analysis | Coronary Artery Disease - economics | Diabetes Mellitus - drug therapy | Insulin Infusion Systems - adverse effects | Diabetic Cardiomyopathies - complications | Insulin - administration & dosage | Postoperative Complications - therapy | Treatment Outcome | Academic Medical Centers | Coronary Artery Bypass - economics | Coronary Artery Bypass - adverse effects | Coronary Artery Disease - complications | Aged | Drug Monitoring | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Coronary artery bypass | Blood sugar | Insulin | Surgery | Diabetes therapy | Diabetics | Patient outcomes | Diabetes | Index Medicus
Journal Article
Pediatric Diabetes, ISSN 1399-543X, 08/2017, Volume 18, Issue 5, pp. 405 - 412
AimTo examine the predictors of direct costs of pediatric type 1 diabetes (T1D) in a hospital-based outpatient clinic in Greece. MethodsThe outpatient records... 
economic expenses | pediatric diabetes | pump therapy | healthcare costs | POPULATION | UNITED-KINGDOM | GERMANY | ADOLESCENTS | ENDOCRINOLOGY & METABOLISM | PEDIATRICS | ECONOMICS | PEOPLE | Glycated Hemoglobin A - analysis | Insulin - economics | Follow-Up Studies | Hypoglycemic Agents - economics | Humans | Cost of Illness | Male | Models, Economic | Diabetes Mellitus, Type 1 - therapy | Combined Modality Therapy - economics | Greece | Hypoglycemia - prevention & control | Hypoglycemic Agents - administration & dosage | Hospitals, Teaching | Female | Insulin Infusion Systems - economics | Hypoglycemia - economics | Hypoglycemia - chemically induced | Child | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Direct Service Costs | Costs and Cost Analysis | Hyperglycemia - economics | Medical Records | Insulin Infusion Systems - adverse effects | Insulin - administration & dosage | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Adolescent | Outpatient Clinics, Hospital | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Cohort Studies | Glycosylated hemoglobin | Clinics | Type 1 diabetes | Diabetes therapy | Medical care, Cost of | Adolescence | Costs | Diabetes mellitus | Hemoglobin | Diabetes | Children | Insulin | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2017, Volume 12, Issue 6, pp. e0178764 - e0178764
Journal Article
Diabetic Medicine, ISSN 0742-3071, 06/2013, Volume 30, Issue 6, pp. e215 - e222
The focus on addressing the rising burden of diabetes has largely been on traditional risk factors such as caloric over‐nutrition and a sedentary lifestyle. In... 
AFRICA | CHRONIC DISEASE | ENDOCRINOLOGY & METABOLISM | SECURITY | TANZANIA | PEOPLE | MELLITUS | HEALTH | DAR-ES-SALAAM | CARE | Diet - economics | Diet, Diabetic - psychology | Glycated Hemoglobin A - analysis | Insulin - economics | Hypoglycemic Agents - economics | Kenya - epidemiology | Overnutrition - physiopathology | Diet - adverse effects | Humans | Middle Aged | Malnutrition - etiology | Male | Socioeconomic Factors | Diabetes Mellitus - economics | Rural Health - economics | Hypoglycemic Agents - administration & dosage | Diet - ethnology | Diabetes Mellitus - etiology | Female | Food Supply - economics | Overnutrition - ethnology | Body Mass Index | Diabetes Mellitus - diet therapy | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Diet, Diabetic - economics | Diabetes Mellitus - drug therapy | Insulin - administration & dosage | Combined Modality Therapy | Malnutrition - economics | Malnutrition - physiopathology | Malnutrition - ethnology | Overnutrition - etiology | Rural Health - ethnology | Diet - psychology | Family Characteristics - ethnology | Overnutrition - economics | Community Health Centers | Diet, Diabetic - adverse effects | Hyperglycemia - epidemiology | Poverty Areas | Diet, Diabetic - ethnology | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Diabetics | Care and treatment | Analysis | Diabetes | Food and nutrition | Food supply | Prevalence studies (Epidemiology) | Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 07/2010, Volume 33, Issue 7, pp. 1484 - 1490
OBJECTIVE - The economic costs of hyperglycemia are substantial. Early detection would allow management to prevent or delay development of diabetes and... 
MEDICAL-CARE COSTS | DIAGNOSIS | US POPULATION | EFFICACY | ENDOCRINOLOGY & METABOLISM | IMPAIRED FASTING GLUCOSE | MELLITUS | IDENTIFICATION | STRATEGIES | United States - epidemiology | United States Department of Veterans Affairs - economics | Blood-Borne Pathogens | Prevalence | Humans |